Study guide

5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring

Key Takeaways Explain This Topic AI

The Rawlins-Thompson classification categorises adverse drug reactions into six mechanistic subtypes: Type A (Augmented/dose-dependent), Type B (Bizarre/idiosyncratic), Type C (Chronic), Type D (Delayed), Type E (End-of-use), and Type F (Failure of therapy).

Therapeutic drug monitoring (TDM) is indicated for agents with a narrow therapeutic index, large inter-individual pharmacokinetic variability, and an established target serum concentration range; sampling must occur at steady-state trough levels.

Digoxin toxicity is classically precipitated by hypokalaemia, hypomagnesaemia, and hypercalcaemia; cardiac manifestations include ventricular bigeminy, junctional tachycardia, and bidirectional ventricular tachycardia, treated with digoxin-specific antibody fragments (DigiFab).

Lithium toxicity (therapeutic target 0.4–0.8 mmol/L) causes coarse tremor, hyperreflexia, ataxia, and encephalopathy; renal lithium clearance is reduced by concurrent NSAIDs, ACE inhibitors, and thiazide diuretics, predisposing to toxicity.

Gentamicin once-daily extended-interval dosing relies on concentration-dependent bacterial killing (high Cmax:MIC ratio) and the post-antibiotic effect; maintaining trough levels < 1 mg/L prevents accumulation that causes irreversible vestibular ototoxicity and acute tubular necrosis.

Last updated: September 2026

Note

Curriculum Focus : The MRCP(UK) Part 1 tests adverse drug reaction (ADR) classifications and practical therapeutic drug monitoring. Candidates must be fluent in the Rawlins-Thompson taxonomy, precise timing of serum sampling, reference therapeutic target windows, laboratory and electrocardiographic manifestations of toxicity, and specific rescue protocols for narrow therapeutic index medications.

An Adverse Drug Reaction (ADR) is defined by the World Health Organization as any noxious, unintended, and undesirable response to a medication occurring at doses routinely used in humans for prophylaxis, diagnosis, or therapy.

The Rawlins-Thompson ADR Taxonomy

The Rawlins and Thompson classification system categorises adverse reactions into six distinct mechanistic groups (Type A through Type F):

Type Category Core Characteristics & Mechanism Clinical Examples & Management

A Augmented • Dose-dependent & predictable from known pharmacology.; • High incidence, low mortality.; • Accounts for > 80% of all clinical ADRs. • Bradycardia from beta-blockers.; • Cough and angioedema from ACE inhibitors.; • Haemorrhage from warfarin or DOACs.; • Hypoglycaemia from sulfonylureas.; • Management : Reduce dose or withhold temporarily.

B Bizarre (Idiosyncratic) • Dose-independent & unpredictable from primary pharmacology.; • Low incidence, high mortality.; • Immune-mediated hypersensitivity or host pharmacogenetic defect. • Penicillin-induced anaphylaxis.; • Drug Reaction with Eosinophilia and Systemic Symptoms ( DRESS ).; • Stevens-Johnson Syndrome ( SJS / TEN ).; • Malignant Hyperthermia ( RYR1 mutation).; • Management : Immediate permanent cessation; report via Yellow Card.

C Chronic (Continuous) • Associated with cumulative dose and prolonged duration of exposure.; • Insidious onset; adaptive tissue changes. • Corticosteroid-induced osteoporosis and adrenal suppression.; • Chloroquine/hydroxychloroquine retinopathy.; • Analgesic nephropathy.; • Amiodarone pulmonary fibrosis and thyroid dysfunction.

D Delayed • Manifests months to years after drug exposure , or in subsequent generations.; • Carcinogenesis or teratogenesis. • Teratogenesis: Thalidomide phocomelia, sodium valproate neural tube defects, isotretinoin embryopathy.; • Secondary malignancies: Alkylating agents (cyclophosphamide) causing acute myeloid leukaemia or bladder transitional cell carcinoma.

E End-of-Use (Withdrawal) • Occurs following abrupt discontinuation of a chronic medication.; • Receptor upregulation or sudden neuroendocrine axis unmasking. • Rebound hypertension following clonidine or beta-blocker withdrawal.; • Acute secondary adrenal crisis following abrupt steroid cessation.; • SSRI discontinuation syndrome (electric shock sensations).; • Benzodiazepine/opioid withdrawal.

F Failure of Therapy • Unexpected therapeutic failure ; disease progression despite prescribed therapy.; • Caused by drug interactions, tolerance, antimicrobial resistance, or enzyme induction. • Oral contraceptive failure when co-prescribed rifampicin.; • Loss of seizure control on carbamazepine due to auto-induction.; • Subtherapeutic vancomycin due to inadequate dosing in augmented renal clearance.

Principles of Therapeutic Drug Monitoring (TDM)

Therapeutic Drug Monitoring involves measuring serum drug concentrations at defined intervals to optimise therapeutic efficacy while avoiding concentration-dependent toxicity. TDM is indicated only when specific criteria are fulfilled:

Narrow Therapeutic Index : Small difference between minimum effective concentration and minimum toxic concentration.

Direct Correlation Between Serum Level and Effect : Established target concentration window correlating with efficacy and safety.

Unpredictable Dose-Concentration Relationship : Wide inter-individual pharmacokinetic variability (due to variable clearance, saturation kinetics, or polymorphic metabolism).

Absence of a Simple Clinical Endpoint : Unlike blood pressure (monitoring antihypertensives) or INR (monitoring warfarin), toxicity or efficacy cannot be directly observed at the bedside without laboratory assays.

Practical Timing of Serum Sampling

Steady State Requirement : Samples must be drawn once the drug has attained steady-state equilibrium ( after 4 to 5 elimination half-lives ), unless acute toxicity is clinically suspected.

Trough Concentrations : For the vast majority of drugs, serum levels are drawn immediately prior to the next scheduled dose ( trough level ).

Key Exception (Digoxin) : Must be sampled at least 6 to 8 hours post-dose (or immediately pre-dose). Digoxin exhibits a prolonged 6-hour distribution phase from plasma into myocardium; sampling before 6 hours yields falsely elevated plasma concentrations that do not reflect tissue receptor engagement.

High-Yield TDM Reference Guide +-----------------------------------------------------------------------------------------+

  • | High-Yield TDM Drug Summary Matrix |
  • +-----------------------------------------------------------------------------------------+
  • | Drug: Target Range: Sampling Time: Key Toxicity Signs: |
  • | Digoxin 0.5 - 0.9 ug/L >= 6h post-dose Ventricular bigeminy, yellow halos |
  • | Lithium 0.4 - 0.8 mmol/L 12h post-dose Coarse tremor, ataxia, dysarthria |
  • | Gentamicin Trough < 1 mg/L Pre-dose trough Vestibular ataxia, ATN (rising Cr) |
  • | Phenytoin 10 - 20 mg/L Trough Nystagmus, ataxia, cerebellar atrophy |
  • | Theophylline 10 - 20 mg/L Trough Tachyarrhythmias, refractory seizures |
  • +-----------------------------------------------------------------------------------------+
  • 1. Digoxin

Therapeutic Range : 0.5–0.9 ug/L in heart failure; 0.8–1.5 ug/L in atrial fibrillation. Toxicity incidence escalates sharply at > 2.0 ug/L.

Mechanism : Inhibits myocardial sarcolemmal Na+/K+ ATPase, increasing intracellular sodium, which reduces calcium extrusion via the Na+/Ca2+ exchanger, enhancing cardiac inotropy.

Precipitating Factors : Hypokalaemia (potassium competes with digoxin for binding at Na+/K+ ATPase; low serum potassium markedly enhances digoxin binding and toxicity), hypomagnesaemia, hypercalcaemia , renal failure, and interacting drugs (amiodarone, verapamil, clarithromycin, spironolactone).

Clinical Manifestations :

Gastrointestinal : Anorexia, nausea, vomiting, abdominal pain (often earliest sign).

Neurological/Visual : Xanthopsia (yellow-green halo vision), blurred vision, confusion, delirium.

Cardiac Arrhythmias : Pathognomonic ventricular bigeminy , bidirectional ventricular tachycardia, paroxysmal atrial tachycardia with variable AV block, junctional escape rhythms, and severe sinus bradycardia.

Management :

Correct potassium (target 4.0–5.0 mmol/L) and magnesium. Note: In acute massive overdose, digoxin causes severe hyperkalaemia by disabling the sodium-potassium pump globally; insulin/dextrose is indicated.

Digoxin-Specific Fab Fragments (DigiFab) : Indications include life-threatening ventricular arrhythmias, refractory bradycardia unresponsive to atropine, serum potassium > 5.0 mmol/L in acute ingestion, or acute ingestion > 10 mg in adults.

2. Lithium

Therapeutic Range : 0.4–0.8 mmol/L for maintenance therapy; 0.8–1.0 mmol/L for acute mania. Monitored exactly 12 hours post-evening dose .

Toxicity Stages :

Mild (1.5–2.0 mmol/L) : Nausea, diarrhoea, polyuria, polydipsia, fine resting tremor converting into a coarse tremor , hyperreflexia.

Moderate (2.0–2.5 mmol/L) : Cerebellar ataxia, dysarthria, coarse myoclonus, nystagmus, fasciculations.

Severe (> 2.5 mmol/L) : Generalised tonic-clonic seizures, encephalopathy, coma, cardiovascular collapse, and the irreversible SILENT syndrome (Syndrome of Irreversible Lithium-Effectuated Neurotoxicity: permanent cerebellar ataxia and cognitive impairment).

Precipitating Drug Interactions (Mnemonic: "NSA") :

N SAIDs: Inhibit renal prostaglandins, reducing renal medullary blood flow and GFR.

S pironolactone / Thiazide diuretics: Induce natriuresis in the distal tubule; the compensatory proximal tubular sodium reabsorption causes equimolar reabsorption of lithium (handled identically to sodium).

A CE Inhibitors / ARBs: Dilate efferent arterioles, reducing GFR and lithium filtration.

Dehydration, vomiting, diarrhoea, and sodium restriction similarly trigger toxicity.

Long-Term Complications : Nephrogenic diabetes insipidus (lithium enters principal cells via ENaC and decouples vasopressin V2 receptor adenylate cyclase, downregulating aquaporin-2 channels), chronic tubulointerstitial nephritis, primary hypothyroidism, and hyperparathyroidism with hypercalcaemia.

Management : Volume expansion with IV 0.9% sodium chloride to promote renal excretion. Haemodialysis is indicated if lithium > 4.0 mmol/L regardless of symptoms, > 2.5 mmol/L with severe neurological manifestations or renal failure, or if clinical deterioration continues despite IV saline.

3. Gentamicin & Aminoglycosides

Pharmacodynamic Target : Concentration-dependent bactericidal killing. Governed by the Cmax : MIC ratio (optimal target >= 10:1) and a prolonged post-antibiotic effect (PAE) .

Extended-Interval Dosing (Hartford Nomogram) : Administering a large single daily dose (5–7 mg/kg) achieves an intense bactericidal peak while allowing serum concentrations to decline to negligible levels before the next dose.

Trough Target : < 1.0 mg/L (pre-dose). Elevated trough concentrations reflect tissue accumulation in renal cortical cells and endolymph/perilymph, directly driving toxicity.

Toxicities :

Nephrotoxicity : Non-oliguric acute tubular necrosis (ATN) caused by pinocytosis of aminoglycoside molecules into proximal tubular brush-border lysosomes. Typically manifests as a rising serum creatinine 5 to 7 days into therapy. Reversible upon cessation.

Ototoxicity : Destruction of sensory hair cells in the cochlea and vestibular apparatus. Cochlear injury causes bilateral high-frequency sensorineural hearing loss and tinnitus; vestibular toxicity causes severe oscillopsia (inability to fixate vision during head movement) and dynamic ataxia. Ototoxicity is frequently permanent and irreversible . Exacerbated by loop diuretics (furosemide) and vancomycin; patients with the mitochondrial 1555A>G mutation in the 12S rRNA gene are exquisitely susceptible to profound deafness after a single dose.

4. Phenytoin

Therapeutic Range : 10–20 mg/L (40–80 umol/L). Governed by saturable zero-order kinetics.

Protein Binding & The Sheiner-Tozer Equation : Phenytoin is 90% bound to plasma albumin. In states of hypoalbuminaemia (cirrhosis, nephrotic syndrome, sepsis) or end-stage renal disease (where uremic toxins displace phenytoin from albumin), the measured total serum phenytoin is falsely depressed. Clinicians must calculate the adjusted concentration: Adjusted Phenytoin (mg/L) = Measured Total Phenytoin / [(0.2 x Serum Albumin [g/dL]) + 0.1]

Dose-Dependent Toxicity Spectrum :

> 20 mg/L (80 umol/L) : Far-lateral horizontal gaze nystagmus (earliest sign).

> 30 mg/L (120 umol/L) : Marked cerebellar ataxia, dysarthria, nausea, diplopia.

> 40 mg/L (160 umol/L) : Severe lethargy, stupor, encephalopathy, and paradoxical increase in seizure frequency.

Idiosyncratic and Chronic Manifestations : Gingival hyperplasia (platelet-derived growth factor upregulation), hirsutism, coarsening of facial features, peripheral sensorimotor neuropathy, osteomalacia (accelerated vitamin D catabolism), megaloblastic anaemia (folate deficiency), cerebellar atrophy, and Dupuytren's contracture.

5. Theophylline

Therapeutic Range : 10–20 mg/L (55–110 umol/L). Non-selective phosphodiesterase inhibitor and adenosine receptor antagonist.

Toxicity : Concentrations > 20 mg/L cause nausea, intractable vomiting, sinus tachycardia, hypokalaemia, and metabolic acidosis. Concentrations > 30 mg/L precipitate life-threatening atrial and ventricular tachyarrhythmias and intractable status epilepticus resistant to conventional antiepileptic therapy.

Critical Interactions : CYP1A2 inhibitors (ciprofloxacin, erythromycin, cimetidine) cause dramatic spikes in theophylline levels.

Management : Multiple-dose activated charcoal (enhances gastrointestinal dialysis), IV beta-blockers (e.g., esmolol) for ventricular tachydysrhythmias, and urgent charcoal haemoperfusion or haemodialysis for levels > 550 umol/L (> 100 mg/L) in acute ingestion.

Loading diagram... Therapeutic Drug Monitoring: Target Troughs & Critical Toxicity Thresholds